Core Concepts
Optimizing treatment for borderline resectable pancreatic cancer through a multidisciplinary approach.
Stats
"PDAC is expected to be the second leading cause of cancer-related deaths by 2030."
"Most patients with PDAC present with metastatic (40%) or locally advanced (40%) disease."
"A minority of patients (20%) present with resectable or borderline resectable (BR) PDAC."
Quotes
"Borderline resectability is a unique category within pancreatic cancer staging that represents tumors that are technically resectable, with or without vascular resection and reconstruction, but that are at high risk of harboring occult metastases at the time of diagnosis or positive margins if pancreatectomy is performed de novo."
"A multidisciplinary approach is essential to optimize each dimension and improve outcomes among patients with BR pancreatic adenocarcinoma."